Mitomycin C in the Treatment of Chronic Myelogenous Leukemia

Total Page:16

File Type:pdf, Size:1020Kb

Mitomycin C in the Treatment of Chronic Myelogenous Leukemia Nagoya ]. med. Sci. 29: 317-344, 1967. MITOMYCIN C IN THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA AKIRA HosHINo 1st Department of Internal Medicine Nagoya University School oj Medicine (Director: Prof. Susumu Hibino) SUMMARY Studies made of the treatment with 66 courses of mitomycin C in 28 patients with chronic myelogenous leukemia are reported. The effect of mitomycin C was investigated according to the relation between drug and host factors, comparison with the effects of other agents, and drug resistance. Patients with less hematological and clinical symptoms responded better to mitomycin C therapy. The remission rate of cases treated intravenously with mitomycin C was 93.8% and of cases treated orally with mitomycin C was 72.0%. The remission rate of the total cases (intravenous and oral) treated with mitomycin C was 77.3%. The therapeutic effect of mitomycin C is considered to be equal or be somewhat superior to the effect of busulfan as a result of data on the occurrence of resistance, cross resistance, development of acute blastic crisis and life span. Busulfan was effective in patients resistant to mitomycin C, and mitomycin C did not clinically show cross resistance to alkylating agents. Two patients resist· ant to mitomycin C recovered the sensitivity to mitomycin C after treatment with busulfan or 6-mercaptopurine. Side effects were observed in 39.4% of 66 cases, but severe side effect causing suspension of mitomycin C was rare. I. INTRODUCTION Human leukemia serves as a useful investigative model in which the de­ finite effect of anti-cancer agents can be evaluated quantitatively by factors such as the improvement of hematological findings and clinical symptoms, the remission rate, and the prologation of life span. In chronic myelogenous leukemia the alkylating agents, busulfan11 - 15 >, TEM 15>- 23>, thio-TEPA12 )15>2"-27 >, nitromin15 >23 >281 - 31 >, have been used for treatment of the disease. 6-mercaptopurine, one of the anti-metabolites, has also been found effective321 - 351 • £ !l!f J'il': Received for publication Oct 17, 1966. Present Address: Aichi Cancer Center, Research Institute, Nagoya. 317 318 A. HOSHINO Recently, following the discovery of mitomycin C36 )-33 ), this new antibiotic has been tried for the treatment of chronic myelogenous leukemia, and the 43 effects of the drug have been reported by Kimura39 )40J, Hibino41 J42 ), Kurita «J, 47 Ota'5l, Yamada46 l, and this author J~sJ_ The patients with chronic myelogenous leukemia were treated at the First Department of Internal Medicine of the Na- goya University School of Medicine over the past 10 years. Among them, 28 patients (total 66 cases of treatment courses) have been under mitomycin C therapy, This paper deals with the analysis of hematological and clinical findings in relation to the effect of mitomycin C, and comparison of the effect of mi­ tomycin C with other agents as regards the remission rate, duration of remis­ sion, and life span. The occurrence of acute blastic crisis, the emergence of the clinical resistance to mitomycin C, and the cross resistance to other drugs, which alters greatly the prognosis of the patients, have also been studied. II. MATERIALS AND METHODS Mitomycin C was obtained from Kyowa Hakko Co. Ltd. An ampule with 2 mg of mitomycin C was dissolved in 20 ml of 5% glucose or in 20 ml of physiological saline. The initial dosage of 1-2 mg was injected intravenously once a day. In case of oral use, 5-6 mg tablets were administered one to three times daily. When the decrease of white blood cell count could not be observed after 2 weeks of initial therapy, the subsequent oral dosage was increased to 9 mg a day. The evaluation of the response of the patients to the drug was carried out by a scoring system following Kimura's criteria (Table 1)~ 0 J 49 l 50 l . Patients obtained points of 40 or more were classified as remission case (complete remission, 60 points or more; partial remission, 59-40 points), and less than 39 points were evaluated as cases of failure of the treatment. The clinical and hematological data prior to the first course of mitomycin Abbreviation of agents Busulfan Myleran, Dimethane sulphonyloxybutane Endoxan Cytoxan, Cyclophosphamide Nitromin Nitrogen mustard N-oxide 6MP 6-mercaptopurine RC-4 P-phenylenediphosphoric acid tetraethy leneimide AL-NM Alanine nitrogen mustard MMC Mitomycin C TEM Triethylene melamine Thio-TEPA Triethylene thiophosphoramide Trenimon Triethylene benzoquinone N. M. Nitrogen mustard TABLE 1. Criteria for Evalution of Response to Chemotherapy in Chronic Leukemia Grade I Score I Grade II Score I Grade III I Score -· 1. Immature cells decrease 1. Immature cells decrease I and leukopoiesis becomes 10 I 5 No improvement ~ · A. normal I or improvement Bone I 0 less than ~ marrow I II 0 2. Erythropoiesis increases 2. Erythropoiesis increases, 5 A-Grade to more than 20% 10 but less than20% ~ ><: I () decrease. but not to z 1. WBC decrease to less 20 1. WBC 10 () than 15,000 less than 15,000 g 2. Immature cells disappear 2. Immature cells decrease t:rJ or decrease to less than 10 to less than 20% 5 No improvement >d B. 10% > I or improvement 0 '1:1 Peripheral less than ><: Hgb contents increase to blood 3. Hgb contents increase to 10 3. 5 B-Grade II 0 more than 80% more than 60% "%j () 4. Platelet counts do not 4. Platelet counts do not ~ decrease to less than 10 decrease to less than 5 ::tl 150,000 80,000 0z c=i SpleP.n decreases, but not I t-' Splenomegaly disappears No improvement t:rJ size, c. or decreases to less than I to less than 1/3 in c::: or improvement 0 Physical 1/3 in size, marked deere- 20 significant reduction of 10 less than ::-1 findings ase of hepatomegaly and hepatomegaly and lymph- C-Grade II t:rJ lymphadenopathy adenopathy >~ No improvement D. Asymptomatic, or marked Definite improvement, or improvement Clinical improvement of leukemic 10 though still symptomatic 5 less than 0 findings symptoms D-Grade II Complete remission: over 60 points :.> .., Partial remission: from 40 to 59 points - TABLE 2. Clinical and Hematological Findings, and Effects of Mitomycin C in the Patients with Chronic Myelogenous Leukemia ~ Clinical and Hematological Findings Before MMC Therapy Effect of Mitomycin C Therapy tj ::r: !>) td <1> ~... ~ I <1> El ~ '0 ~- ~ ... ~ ... ~tj Ul !':! El ~-~ ~g~ SUJ !>) ~~ ...... ro r-+ C'tl ro r-+ ('1) t1> Case Age Sex Ol(bo" <1>'0 ::1'< '< so.otjgO,otj El !':! t:x:l o-liO! WBC Hgb oq(; ...0 l:ll PL I g~ !:9-g.g ::! ~ 0 3 t:1 w' O<l E.o ~·oq E.~» ~-o ~ ~·'"' 1>'::> <1> '< !':! 0 .., 0 ~o El '0'0 () El ~- ~~r~~ ~-~~ <1> <1> ~ ~.<·~g; . < ;~ 8.~ ~ '<• oq ~::r ... ::r· <1> g<~>o.lo'<~>o. o g e:. I e:. '< ::> ::> I I % x10' I % -% % '< (rug) I (rug) (month) ** (month) I. G. 38 M 84,600 91 18.6 6.5 0 0.2 - I + - 2-3 37 15 0.5 I PR 46 A.W. 61 F 72,600 65 25.5 0 0 - - 1 26 26 6 CR 62 K.A. 49 F 72.800 79 10.0 0 0 * - - 0.5-1 28 28 5 CR 24 T . N. 22 M 110,600 85 14.0 23.0 0 0.4 *+ - - 0.5-2 71 39 8 CR 49 T. I. 34 M 95,400 97 10.3 26.0 0 2.2 + - - 1 13 13 5 CR 69 K.T. 28 M 31,400 68 19.5 66 .0 5.5 6.6 - 1-2 - - - NE 23 K.O. 34 F 265,800 78 16.3 19.5 0 * *- - 1 70 70 3 CR 46 ?> 30 F 153,200 54 28.2 28.0 0 0.9 - 1-2 ::r: s.s. * + 61 61 14 CR 56 0 K.M. 24 M 90,600 87 42.0 0 0 *+ - - 5* 70 14 1.5 CR 56 K.W. 36 F 77,400 51 - - 5* - - - NE 46 ~ -- - I - K.S . 34 M 70,000 76 28.4 0 * 5* - - NE 43 z0 M.K. 44 54,000 21.0 0 - F 62 I 49.8 * 5* 85 17 7.5 CR 19 T.S. 34 M 66,800 60 56.8 25.5 0.5 3.4 *+ I *+ + 5* 70 14 2.5 CR 17t Y.K. 30 F 144,0001 49 . 5.8 18.0 0.5 2.2 + 5* - - - NE 3 G.N. 55 M 299,200; 53 21.8 38.0 1.0 2.4 * *+ - 5* 105 38 3 I CR 18 M.T. 19 F 185,000 57 152.5 27.5 0 1.3 * - 5* 75 I 15 11 CR 44t s .s. 19 M 380.000 65 14.1 25.5 1.0 1.2 * * - 5* 220 44 2 CR 42t Z . Y. 67 M 199,600 25 10.3 1.0 *- *+ - 5* 210 42 13 CR 23 T.O. 23 M 313,700 56 29.7 36.5 0.5 1.6 + 5* - - - NE 30t s.o. 46 M 70,600 80 19.6 36.5 0.5 * *- - 5-7.5* 450 86 9.5 CR 37t K.O. 38 M 42,800 1 85 82.5 19.0 0.5 1.6 *- -- 4* 16 4 0.5 CR 12 s.s. 47 M 46,000 80 91.7 39.0 2.0 0.4 + - 4-6* 168 28 3 CR 23t F. I. 36 F 353.000 64 40.8 58.5 3.0 0 *+ - 6* - - - NE 1St T . S. 22 M 553,000 46 33.5 60.0 3.0 3.2 * 6-9* - - - NE 22t T.M.
Recommended publications
  • Mitomycin C: Indications for Use and Safe Practice in Ophthalmology Published by American Society of Ophthalmic Registered Nurses
    Mitomycin C: Indications for Use and Safe Practice in Ophthalmology Published by American Society of Ophthalmic Registered Nurses Editor Susan Clouser, RN, MSN, CRNO American Society of Ophthalmic Registered Nurses 655 Beach Street, San Francisco, CA 94109 1 This publication includes independent authors’ guidelines for the safe use and handling of mitomycin C in ophthalmic practices. Readers should use these guidelines as a resource only. These guidelines should never take precedence over manufacturers’ recommended practices, facilities policies and procedures, or compliance with federal regulations. Information in this publication may assist facilities in developing policies and procedures specifc to their needs and practice environment. American Society of Ophthalmic Registered Nurses For questions regarding content or association issues contact ASORN at [email protected] or 1.415.561.8513. Copyright © 2011 by American Society of Ophthalmic Registered Nurses American Society of Ophthalmic Registered Nurses has the exclusive rights to reproduce this work, to prepare derivative works from this work, to publicly distribute this work, to publicly perform this work and to publicly display this work. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of American Society of Ophthalmic Registered Nurses. Printed in the United States of America 10 9 8 7 6 5 4 3 2 1 ACKNOWLEDGMENTS The development of this educational resource would not have been possible without the knowledge and expertise of the ophthalmologists and ophthalmic registered nurses who wrote the content and the subsequent reviewers who provided valuable input.
    [Show full text]
  • Induction with Mitomycin C, Doxorubicin, Cisplatin And
    British Journal of Cancer (1999) 80(12), 1962–1967 © 1999 Cancer Research Campaign Article no. bjoc.1999.0627 Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study RL Hong1, TS Sheen2, JY Ko2, MM Hsu2, CC Wang1 and LL Ting3 Departments of 1Oncology, 2Otolaryngology and 3Radiation Therapy, National Taiwan University Hospital, National Taiwan University, No. 7, Chung-Shan South Road, Taipei 10016, Taiwan Summary The combination of cisplatin and 5-fluorouracil (5-FU) (PF) is the most popular regimen for treating metastatic nasopharyngeal carcinoma (NPC) but it is limited by severe stomatitis and chronic cisplatin-related toxicity. A novel approach including induction with mitomycin C, doxorubicin and cisplatin (MAP) and subsequent maintenance with weekly 5-FU and leucovorin (FL) were designed with an aim to reduce acute and chronic toxicity of PF. Thirty-two patients of NPC with measurable metastatic lesions in the liver or lung were entered into this phase II trial. Mitomycin C 8 mg m–2, doxorubicin 40 mg m–2 and cisplatin 60 mg m–2 were given on day 1 every 3 weeks as initial induction. After either four courses or remission was achieved, patients received weekly dose of 5-FU 450 mg m–2 and leucovorin 30 mg m–2 for maintenance until disease progression. With 105 courses of MAP given, 5% were accompanied by grade 3 and 0% were accompanied by grade 4 stomatitis. The dose-limiting toxicity of MAP was myelosuppression. Forty per cent of courses had grade 3 and 13% of courses had grade 4 leukopenia.
    [Show full text]
  • The Limitations of DNA Interstrand Cross-Link Repair in Escherichia Coli
    Portland State University PDXScholar Dissertations and Theses Dissertations and Theses 7-12-2018 The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli Jessica Michelle Cole Portland State University Follow this and additional works at: https://pdxscholar.library.pdx.edu/open_access_etds Part of the Biology Commons Let us know how access to this document benefits ou.y Recommended Citation Cole, Jessica Michelle, "The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli" (2018). Dissertations and Theses. Paper 4489. https://doi.org/10.15760/etd.6373 This Thesis is brought to you for free and open access. It has been accepted for inclusion in Dissertations and Theses by an authorized administrator of PDXScholar. Please contact us if we can make this document more accessible: [email protected]. The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli by Jessica Michelle Cole A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Biology Thesis Committee: Justin Courcelle, Chair Jeffrey Singer Rahul Raghavan Portland State University 2018 i Abstract DNA interstrand cross-links are a form of genomic damage that cause a block to replication and transcription of DNA in cells and cause lethality if unrepaired. Chemical agents that induce cross-links are particularly effective at inactivating rapidly dividing cells and, because of this, have been used to treat hyperproliferative skin disorders such as psoriasis as well as a variety of cancers. However, evidence for the removal of cross- links from DNA as well as resistance to cross-link-based chemotherapy suggests the existence of a cellular repair mechanism.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,921,361 B2 Cmiljanovic Et Al
    USOO892.1361 B2 (12) United States Patent (10) Patent No.: US 8,921,361 B2 Cmiljanovic et al. (45) Date of Patent: Dec. 30, 2014 (54) TRIAZINE, PYRIMIDINE AND PYRIDINE 409/04 (2013.01); C07D 413/04 (2013.01); ANALOGS AND THEIR USEAS C07D 413/14 (2013.01); C07D 417/04 THERAPEUTICAGENTS AND DAGNOSTIC (2013.01); C07D 417/14 (2013.01); C07D PROBES 491/048 (2013.01); C07D491/147 (2013.01); C07D 495/04 (2013.01); C07D 495/14 (2013.01); C07D498/04 (2013.01); C07D (75) Inventors: Vladimir Cmiljanovic, Basel (CH): 513/04 (2013.01); C07D 519/00 (2013.01) Natasa Cmiljanovic, Basel (CH); Bernd USPC .......................................... 514/232.2:544/83 Giese, Fribourg (CH); Matthias (58) Field of Classification Search Wymann, Bern (CH) None See application file for complete search history. (73) Assignee: University of Basel, Basel (CH) (56) References Cited (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S. PATENT DOCUMENTS U.S.C. 154(b) by 60 days. 5,489,591 A * 2/1996 Kobayashi et al. ........... 514,245 (21) Appl. No.: 13/128,436 7,173,029 B2 2/2007 Hayakawa et al. 8,217,036 B2 * 7/2012 Venkatesan et al. ....... 514,232.2 (22) PCT Filed: Nov. 10, 2009 2010 OO69629 A1 3/2010 Shimma et al. (86). PCT No.: PCT/B2O09/OOT404 FOREIGN PATENT DOCUMENTS EP 1864 665 A1 12/2007 S371 (c)(1), WO 2005/028444 A1 3, 2005 (2), (4) Date: Jul. 1, 2011 WO 2007 1271.75 A2 11/2007 WO 2008/O18426 A1 2, 2008 (87) PCT Pub.
    [Show full text]
  • How to Manage Acute Promyelocytic Leukemia
    Leukemia (2012) 26, 1743 -- 1751 & 2012 Macmillan Publishers Limited All rights reserved 0887-6924/12 www.nature.com/leu HOW TO MANAGEy How to manage acute promyelocytic leukemia J-Q Mi, J-M Li, Z-X Shen, S-J Chen and Z Chen Acute promyelocytic leukemia (APL) is a unique subtype of acute myeloid leukemia (AML). The prognosis of APL is changing, from the worst among AML as it used to be, to currently the best. The application of all-trans-retinoic acid (ATRA) to the induction therapy of APL decreases the mortality of newly diagnosed patients, thereby significantly improving the response rate. Therefore, ATRA combined with anthracycline-based chemotherapy has been widely accepted and used as a classic treatment. It has been demonstrated that high doses of cytarabine have a good effect on the prevention of relapse for high-risk patients. However, as the indications of arsenic trioxide (ATO) for APL are being extended from the original relapse treatment to the first-line treatment of de novo APL, we find that the regimen of ATRA, combined with ATO, seems to be a new treatment option because of their targeting mechanisms, milder toxicities and improvements of long-term outcomes; this combination may become a potentially curable treatment modality for APL. We discuss the therapeutic strategies for APL, particularly the novel approaches to newly diagnosed patients and the handling of side effects of treatment and relapse treatment, so as to ensure each newly diagnosed patient of APL the most timely and best treatment. Leukemia (2012) 26, 1743--1751; doi:10.1038/leu.2012.57 Keywords: acute promyelocytic leukemia (APL); all-trans-retinoic acid (ATRA); arsenic trioxide (ATO) INTRODUCTION In this review, we introduce the therapeutic strategies of APL, Acute promyelocytic leukemia (APL) is a distinct subtype of acute including the treatment of newly diagnosed and relapsed myeloid leukemia (AML) characterized by its abnormal promye- patients, as well as the ways to deal with the side effects.
    [Show full text]
  • DRUG NAME: Thioguanine
    Thioguanine DRUG NAME: Thioguanine SYNONYM(S): 2-amino-6-mercaptopurine,1 6-TG, TG COMMON TRADE NAME(S): LANVIS® CLASSIFICATION: antimetabolite, cytotoxic2 Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION: Thioguanine is a purine antagonist.1 It is a pro-drug that is converted intracellullarly directly to thioguanine monophosphate3 (also called 6-thioguanylic acid)4 (TGMP) by the enzyme hypoxanthine-guanine phosphoribosyl transferase (HGPRT). TGMP is further converted to the di- and triphosphates, thioguanosine diphosphate (TGDP) and thioguanosine triphosphate (TGTP).5 The cytotoxic effect of thioguanine is a result of the incorporation of these nucleotides into DNA. Thioguanine has some immunosuppressive activity.1 Thioguanine is specific for the S phase of the cell cycle.6 PHARMACOKINETICS: Oral Absorption • incomplete and variable (14-46%)7 • preferably taken on an empty stomach8; may be taken with food if needed • children9: <20% Distribution crosses the placenta10 cross blood brain barrier? negligible11 volume of distribution12 148 mL/kg plasma protein binding no information found Metabolism hepatic10 activation by4: • hypoxanthine-guanine phosphoribosyl transferase (HGPRT) elimination by4: • guanase to 6-thioxanthine • thiopurine methyltransferase (TPMT) to 2-amino-6-methyl thiopurine active metabolites3,4 thiopurine nucleotides inactive metabolites4 6-thioxanthine, 2-amino-6-methyl thiopurine Excretion renal excretion12; initially intact drug, then metabolites urine12
    [Show full text]
  • Arsenic Trioxide As a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study
    Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study Shakeel Modak1, Pat Zanzonico2, Jorge A. Carrasquillo3, Brian H. Kushner1, Kim Kramer1, Nai-Kong V. Cheung1, Steven M. Larson3, and Neeta Pandit-Taskar3 1Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York; 2Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York; and 3Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York sponse rates when compared with historical data with 131I-MIBG Arsenic trioxide has in vitro and in vivo radiosensitizing properties. alone. We hypothesized that arsenic trioxide would enhance the efficacy of Key Words: radiosensitization; neuroblastoma; malignant the targeted radiotherapeutic agent 131I-metaiodobenzylguanidine pheochromocytoma/paraganglioma; MIBG therapy 131 ( I-MIBG) and tested the combination in a phase II clinical trial. J Nucl Med 2016; 57:231–237 Methods: Patients with recurrent or refractory stage 4 neuroblas- DOI: 10.2967/jnumed.115.161752 toma or metastatic paraganglioma/pheochromocytoma (MP) were treated using an institutional review board–approved protocol (Clinicaltrials.gov identifier NCT00107289). The planned treatment was 131I-MIBG (444 or 666 MBq/kg) intravenously on day 1 plus arsenic trioxide (0.15 or 0.25 mg/m2) intravenously on days 6–10 and 13–17. Toxicity was evaluated using National Cancer Institute Common Metaiodobenzylguanidine (MIBG) is a guanethidine analog Toxicity Criteria, version 3.0. Response was assessed by Interna- that is taken up via the noradrenaline transporter by neuroendo- tional Neuroblastoma Response Criteria or (for MP) by changes in crine malignancies arising from sympathetic neuronal precursors 123I-MIBG or PET scans.
    [Show full text]
  • Severe Myelotoxicity Associated with Thiopurine S-Methyltransferase*3A
    Case Report DOI: 10.4274/tjh.2013.0082 Severe Myelotoxicity Associated with Thiopurine S-Methyltransferase*3A/*3C Polymorphisms in a Patient with Pediatric Leukemia and the Effect of Steroid Therapy Pediatrik Bir Lösemi Olgusunda Tiyopurin S-Metiltransferaz *3A/*3C Polimorfizmi ile İlişkili Ağır Miyelotoksisite-Steroid Tedavisinin Etkisi Burcu Fatma Belen1, Türkiz Gürsel1, Nalan Akyürek2, Meryem Albayrak3, Zühre Kaya1, Ülker Koçak1 1Gazi University Faculty of Medicine, Department of Pediatric Hematology, Ankara, Turkey 2Gazi University Faculty of Medicine, Department of Pathology, Ankara, Turkey 3Kırıkkale University Faculty of Medicine, Department of Pediatric Hematology, Ankara, Turkey Abstract: Myelosuppression is a serious complication during treatment of acute lymphoblastic leukemia and the duration of myelosuppression is affected by underlying bone marrow failure syndromes and drug pharmacogenetics caused by genetic polymorphisms. Mutations in the thiopurine S-methyltransferase (TPMT) gene causing excessive myelosuppression during 6-mercaptopurine (MP) therapy may cause excessive bone marrow toxicity. We report the case of a 15-year-old girl with T-ALL who developed severe pancytopenia during consolidation and maintenance therapy despite reduction of the dose of MP to 5% of the standard dose. Prednisolone therapy produced a remarkable but transient bone marrow recovery. Analysis of common TPMT polymorphisms revealed TPMT *3A/*3C. Key Words: Myelosuppression, Thiopurine S-methyl transferase, Acute leukemia Özet: Miyelosupresyon,
    [Show full text]
  • List of Drugs Not Repackaged by Safecor Health
    Drugs Not Repackaged by Safecor Health The following tables list specific medications that are not repackaged by Safecor Health due to regulatory restrictions or specific manufacturer requirements. The items not repackaged are alphabetically listed below, both by brand name (table 1) and generic name (table 2). Please note: Safecor Health cannot repackage any beta lactam antibiotics (such as penicillins, amoxicillin and cephalosporins) or potent chemotherapeutic agents. Also, due to FDA restrictions, we cannot repackage half- or quarter-tabs, compounded or diluted drugs, powders, and ointments or creams. Safecor Health can repackage most hazardous drugs on the NIOSH list. Contact us for a complete list of hazardous drugs repackaged by Safecor Health. Table 1. Do Not Repackage Drugs Sorted Alphabetically by Brand Name Brand Name(s) Generic Name(s) Reason Item Cannot Be Repackaged Adrucil Fluorouracil Potent chemotherapy agent Aspirin and Extended-Release Specific manufacturer recommendations for very Aggrenox Dipyridamole limited expiration dating Albenza Albendazole Cost per dose prohibitive Alkeran Melphalan Potent chemotherapy agent Augmentin Amoxicillin and Clavulanate Potassium Safecor Health does not repackage this drug class Manufacturer states, "dispense in original container," Belsomra Suvorexant on the drug label Manufacturer states, "dispense in original container," Biktarvy Bictegravir, Emtricitabine and Tenofovir Alafenamide on the drug label Bion Tears Dextran, Hypromellose Ophthalmic Drops Sterile and unpreserved CeeNU Lomustine
    [Show full text]
  • Busulfan–Melphalan Followed by Autologous Stem Cell
    Bone Marrow Transplantation (2016) 51, 1265–1267 © 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 0268-3369/16 www.nature.com/bmt LETTER TO THE EDITOR Busulfan–Melphalan followed by autologous stem cell transplantation in patients with high-risk neuroblastoma or Ewing sarcoma: an exposed–unexposed study evaluating the clinical impact of the order of drug administration Bone Marrow Transplantation (2016) 51, 1265–1267; doi:10.1038/ survival (OS) was the time from study entry (that is, the first day bmt.2016.109; published online 25 April 2016 of HDC) to death or the last follow-up, whichever occurred first. EFS was the time from study entry to disease progression, a second malignancy, death or the last follow-up, whichever High-dose chemotherapy (HDC) and autologous stem cell occurred first. OS and EFS were estimated using the Kaplan–Meier transplantation (ASCT) have improved the prognosis of high-risk method. Patients from the two treatment groups (Bu–Mel neuroblastoma and metastatic Ewing sarcoma.1,2 The impact of and Mel–Bu) of the same age at diagnosis were matched. the drugs in the HDC regimen was first demonstrated in a The association of the treatment group with toxicity and study performed in the Gustave Roussy Pediatrics Department. efficacy outcomes was assessed using Cox regression models It showed improved survival for patients with stage 4 stratified on matched pairs and adjusted for other confounding neuroblastoma who received a combination of busulfan (Bu) factors, such as the year of diagnosis, VOD prophylaxis and age at and melphalan (Mel).3 These results were confirmed in a diagnosis.
    [Show full text]
  • Sex-Specific Effects of Cytotoxic Chemotherapy Agents
    www.impactaging.com AGING, April 2016, Vol 8 No 4 Research Paper Sex‐specific effects of cytotoxic chemotherapy agents cyclophospha‐ mide and mitomycin C on gene expression, oxidative DNA damage, and epigenetic alterations in the prefrontal cortex and hippocampus – an aging connection 1 2 2 2 Anna Kovalchuk , Rocio Rodriguez‐Juarez , Yaroslav Ilnytskyy , Boseon Byeon , Svitlana 3,4 4 3 1,5,6 2,5 Shpyleva , Stepan Melnyk , Igor Pogribny , Bryan Kolb, , and Olga Kovalchuk 1 Department of Neuroscience, University of Lethbridge, Lethbridge, AB, T1K3M4, Canada 2 Department of Biological Sciences, University of Lethbridge, Lethbridge, AB, T1K3M4, Canada 3 Division of Biochemical Toxicology, Food and Drug Administration National Center for Toxicological Research, Jefferson, AR 72079, USA 4Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72202, USA 5 Alberta Epigenetics Network, Calgary, AB, T2L 2A6, Canada 6 Canadian Institute for Advanced Research, Toronto, ON, M5G 1Z8, Canada Key words: chemotherapy, chemo brain, epigenetics, DNA methylation, DNA hydroxymethylation, oxidative stress, transcriptome, aging Received: 01/08/16; Accepted: 01/30/1 6; Published: 03/30/16 Corresponden ce to: Bryan Kolb, PhD; Olga Kovalchuk, PhD; E‐mail: [email protected]; [email protected] Copyright: Kovalchuk et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Abstract: Recent research shows that chemotherapy agents can be more toxic to healthy brain cells than to the target cancer cells. They cause a range of side effects, including memory loss and cognitive dysfunction that can persist long after the completion of treatment.
    [Show full text]
  • Intravesical Administration of Therapeutic Medication for the Treatment of Bladder Cancer Jointly Developed with the Society of Urologic Nurses and Associates (SUNA)
    Intravesical Administration of Therapeutic Medication for the Treatment of Bladder Cancer Jointly developed with the Society of Urologic Nurses and Associates (SUNA) Revised: June 2020 Workgroup Members: AUA: Roxy Baumgartner, RN, APN-BC; Sam Chang, MD; Susan Flick, CNP; Howard Goldman, MD, FACS; Jim Kovarik, MS, PA-C; Yair Lotan, MD; Elspeth McDougall, MD, FRCSC, MHPE; Arthur Sagalowsky, MD; Edouard Trabulsi, MD SUNA: Debbie Hensley, RN; Christy Krieg, MSN, CUNP; Leanne Schimke, MSN, CUNP I. Statement of Purpose: To define the performance guidance surrounding the instillation of intravesical cytotoxic, immunotherapeutic, and/or therapeutic drugs via sterile technique catheterization for patients with non-muscle invasive bladder cancer (NMIBC, urothelial carcinoma). II. Population: Adult Urology III. Definition: Intravesical therapy involves instillation of a therapeutic agent directly into the bladder via insertion of a urethral catheter. IV. Indications: For administration of medication directly into the bladder via catheterization utilizing sterile technique for NMIBC treatment. V. Guidelines and Principles: Health care personnel (MD, NP, PA, RN, LPN, or MA) performing intravesical therapy must be educated, demonstrate competency, and understand the implications of non-muscle invasive bladder cancer. (Scope of practice for health care personnel listed may vary based on state or institution). This should include associated health and safety issues regarding handling of cytotoxic, and immunotherapeutic agents; and documented competency of safe practical skills. At a minimum, each institution or office practice setting should implement an established, annual competency program to review safety work practices and guidelines regarding storage, receiving, handling/ transportation, administration, disposal, and handling a spill of hazardous drugs. (Mellinger, 2010) VI.
    [Show full text]